Sebastian Grosicki

Head of Department, MD PhD, Ass. Prof.

Medical University of Silesia

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sebastian Grosicki is the Head of Department and Associate Professor at the Medical University of Silesia, Poland. His research focuses on the treatment of hematologic malignancies, particularly multiple myeloma and chronic lymphocytic leukemia, as evidenced by his recent publications on therapies including Elranatamab and Zanubrutinib. He has also contributed to studies on the impact of SARS-CoV-2 on patients with these conditions, alongside exploring the role of autophagy in acute myeloid leukemia development.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (4)

Christian Sebastian Michel

Attending physician, Head of Myeloma Service

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY

View details

Karolina Kociszewska

Medical University of Silesia

POLAND

View details

Nicola Dąbrowska-Szeja

Teaching assistant, PhD

Medical University of Silesia

POLAND

View details

Lidia Usnarska-Zubkiewicz

Wroclaw Medical University

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sebastian Grosicki

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Elranatamab: a new promising BispAb in multiple myeloma treatment

SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies

The role of autophagy in acute myeloid leukemia development

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary

Quality of life in patients with lymphoproliferative neoplasms at diagnosis and after the first-line treatment

Collaborators (4)

Christian Sebastian Michel

Karolina Kociszewska

Nicola Dąbrowska-Szeja

Lidia Usnarska-Zubkiewicz

Make your next move.